University Hospital Cologne
- Address
- Kerpener Strasse 62, Lindenthal, 50937 Cologne, Germany
Eye Diseases at University Hospital Cologne
Clinical research in ophthalmology focuses on geographic atrophy secondary to age-related macular degeneration, with studies designed to explore whether new treatments can slow disease progression and protect vision.
- Evaluating potential therapies for geographic atrophy linked to age-related macular degeneration
- Assessing the effect of new approaches on lesion growth and eye disease progression
- Improving treatment options for advanced retinal disease
These trials aim to support better care for people facing progressive vision loss and to expand the range of available eye disease treatments.
Hemic and Lymphatic Diseases
The hematology research program includes studies in immune-mediated thrombotic thrombocytopenic purpura and related thrombotic microangiopathy conditions, with a focus on improving safety and treatment effectiveness in acute care settings.
- Testing new treatment options for immune-mediated thrombotic thrombocytopenic purpura
- Studying therapies for thrombotic microangiopathy and closely related blood disorders
- Evaluating how well emerging treatments are tolerated in urgent clinical situations
This work at University Hospital Cologne supports efforts to improve outcomes in rare but serious blood disorders.
Psychiatry and Psychology
In mental health research, the site is studying schizophrenia, with trials aimed at understanding whether new therapies can improve cognitive function and daily functioning for adults living with the condition.
- Assessing treatments intended to improve cognitive impairment in schizophrenia
- Exploring better ways to support thinking and memory symptoms
- Evaluating the overall usefulness of new psychiatric therapies
These studies reflect a broader effort to advance care in psychiatry by addressing both symptoms and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 27 therapeutic areas and 15 of 650 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 591 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 136 by active trials.
- 1Novartis Pharma AG14active
lock +135 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG36trials
lock +73 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Hospital Cologne
lock Showing 1 of 486 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD) | Bayer AG | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 650 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 41 | Unknown | 2018-03-06 | 2026-07-09 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.